tiprankstipranks
Family Office of America (FOFA)
OTHER OTC:FOFA
US Market
Want to see FOFA full AI Analyst Report?

Family Office of America (FOFA) AI Stock Analysis

8 Followers

Top Page

FOFA

Family Office of America

(OTC:FOFA)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 5.2)
Rating:53Neutral
Price Target:
$1.00
▲(0.00% Upside)
Action:N/A
Date:05/19/26
The score is primarily supported by improved TTM financial trends (higher revenue, reduced losses/cash burn, and a currently debt-free balance sheet). This is tempered by ongoing unprofitability and a volatile historical financial profile, while technicals are moderately constructive but valuation remains expensive (high P/E with no dividend yield).
Positive Factors
Sustained TTM revenue rebound
The company’s trailing-twelve-month revenue rose materially to roughly $1.0M, signalling recovering demand and better execution versus the prior year. Durable top-line improvement supports scale opportunities, helps absorb fixed costs, and creates a clearer path to sustainable margins if maintained.
Negative Factors
Ongoing unprofitability and negative ROE
Despite revenue recovery, the company still posts a negative net margin (~-11%) and negative ROE, indicating it has not yet converted top-line gains into shareholder returns. Persistent losses can deplete resources and delay self-sustaining growth absent sustained margin improvement or cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained TTM revenue rebound
The company’s trailing-twelve-month revenue rose materially to roughly $1.0M, signalling recovering demand and better execution versus the prior year. Durable top-line improvement supports scale opportunities, helps absorb fixed costs, and creates a clearer path to sustainable margins if maintained.
Read all positive factors

Family Office of America (FOFA) vs. SPDR S&P 500 ETF (SPY)

Family Office of America Business Overview & Revenue Model

Company Description
Family Office of America, Inc. specializes in delivering a broad spectrum of services designed for family offices. Their expertise spans accounting and tax strategy, comprehensive wealth and asset administration, meticulous estate planning, robust...
How the Company Makes Money
null...

Family Office of America Financial Statement Overview

Summary
TTM results show a meaningful rebound: revenue improved sharply and losses/cash burn narrowed, supported by a currently debt-free balance sheet with positive equity. However, the business is still loss-making with negative ROE, and the recent history of very large losses, prior negative equity, and heavy cash outflows increases stability and execution risk.
Income Statement
24
Negative
Balance Sheet
57
Neutral
Cash Flow
29
Negative
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.00M221.76K0.000.000.000.00
Gross Profit950.98K221.76K0.00-17.25K0.000.00
EBITDA-23.55K-449.15K-95.01K-223.00K-560.90K-1.14M
Net Income-125.64K-492.75K-100.48K-805.00K-921.00K-1.73M
Balance Sheet
Total Assets2.26M1.54M20.58K2.43K295.46K800.06K
Cash, Cash Equivalents and Short-Term Investments343.22K155.80K13.59K2.43K69.86K528.28K
Total Debt507.75K300.00K0.009.10K31.19K0.00
Total Liabilities1.29M878.53K44.02K525.39K71.51K29.65K
Stockholders Equity966.11K664.51K-23.44K-522.96K223.95K770.41K
Cash Flow
Free Cash Flow-13.12K-822.79K-89.37K-76.53K-558.43K-794.63K
Operating Cash Flow-13.12K-262.19K-89.37K-76.53K-558.43K-792.84K
Investing Cash Flow-598.88K-560.60K0.000.000.00-1.79K
Financing Cash Flow390.00K965.00K100.53K9.10K100.00K1.25M

Family Office of America Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$22.46M-0.38-248.91%58.54%
53
Neutral
$36.42M-203.39-60.28%45.98%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$11.92M>-0.01-68.21%
41
Neutral
$5.74M-0.20-246.04%54.48%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FOFA
Family Office of America
1.20
0.52
75.95%
SNGX
Soligenix
0.39
-0.81
-67.75%
CLRB
Cellectar Biosciences
2.81
-1.99
-41.46%
AKTX
Akari Therapeutics
10.41
-36.39
-77.76%
MGRX
Mangoceuticals, Inc.
0.47
-1.02
-68.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 19, 2026